glu-asp-arg profile

pinealon: synthetic tripeptide that increases cell viability by suppression of free radical levels and activating proliferative processes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Glu-Asp-Arg : A tripeptide composed of L-glutamic acid, L-aspartic acid, and L-arginine joined in sequence by peptide linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	10273502
CHEBI ID	156374
SCHEMBL ID	3839057
MeSH ID	M0571175

Synonym
e-d-r
h-glu-asp-arg-oh
l-glu-l-asp-l-arg
glu-asp-arg
pinealon
CHEBI:156374
l-alpha-glutamyl-l-alpha-aspartyl-l-arginine
SCHEMBL3839057
l-glutamyl-l-aspartyl-l-arginine
glutamyl-aspartyl-arginine
CS-0635571
HY-P4052

Role	Description
neuroprotective agent	Any compound that can be used for the treatment of neurodegenerative disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
tripeptide	Any oligopeptide that consists of three amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (11.76)	29.6817
2010's	13 (76.47)	24.3611
2020's	2 (11.76)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (5.26%)	5.53%
Reviews	2 (10.53%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (84.21%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
cytosine [no description available]	2.06	1	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.	2.06	1	0	phenanthridines	fluorochrome; intercalator
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	2.06	1	0	fluorescein isothiocyanate
alanyl-glutamyl-aspartyl-glycine epithalamin: epiphysial polypeptoid extract	2.47	2	0
lysylglutamic acid lysylglutamic acid: a geroprotective agent. Lys-Glu : A dipeptide formed from L-lysine and L-glutamic acid residues.	2.06	1	0	dipeptide	metabolite
acth (4-7), pro-gly-pro- [no description available]	3.18	1	0
lysyl-glutamyl-aspartic acid [no description available]	4.73	6	1	oligopeptide

Condition	Relationship Strength	Studies	Trials
Acute Confusional Senile Dementia [description not available]	3.17	1	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	3.17	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.79	3	0
Behavior Disorders [description not available]	3.46	1	1
Diseases, Occupational [description not available]	3.46	1	1
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	3.46	1	1
Central Nervous System Disease [description not available]	3	1	0
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	3	1	0
Anoxemia [description not available]	2.47	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.48	2	0
Acute Disease Disease having a short and relatively severe course.	2.1	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.47	2	0
Chronic Illness [description not available]	2.11	1	0
Clerambault Syndrome [description not available]	2.11	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.11	1	0
Delayed Effects, Prenatal Exposure [description not available]	2.04	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.04	1	0
Extravascular Hemolysis [description not available]	2.04	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.04	1	0
Carotid Artery Narrowing [description not available]	2.06	1	0
Carotid Stenosis Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp 822-3)	2.06	1	0
Aging, Premature Changes in the organism associated with senescence, occurring at an accelerated rate.	2.07	1	0
Abnormalities, Autosome [description not available]	2.07	1	0

glu-asp-arg

Description

Cross-References

Synonyms (12)

Roles (1)

Drug Classes (1)

Research

Studies (17)

Study Types